Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients

• Published in: Swiss medical weekly Vol. 143; no. 3536; p. w13850
• Main Authors: Wu, Sheng-Wen, Tsai, Hui-Ching, Tsai, Pao-Yu, Hung, Tung-Wei, Chang, Horng-Rong, Lian, Jong-Da
• Format: Journal Article
• Language: English
• Published: Switzerland SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 27.08.2013
• Subjects: adherence; Adult; advagraf; Aged; Delayed-Action Preparations; Drug Administration Schedule; efficacy; Female; Graft Rejection - prevention & control; Humans; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - blood; Kidney Transplantation; Male; Medication Adherence; Middle Aged; prograf; renal transplantation; Tacrolimus - administration & dosage; Tacrolimus - blood; Treatment Outcome
• ISSN: 1424-7860; 1424-3997
• DOI: 10.4414/smw.2013.13850

The once-daily tacrolimus formulation (Advagraf®), with the potential for improving medical adherence, has been advocated to improve long-term kidney allograft outcomes. However, experience with late conversion from the twice-daily tacrolimus formulation (Prograf®) to Advagraf in the daily care of stable kidney transplant recipients has been limited. The aim of this study was to observe the efficacy and safety of conversion from Prograf to Advagraf in chronic stable kidney transplant recipients in routine clinical practice. The recruited patients had postconversion follow-up at least once monthly for a total of six months, unless they had discontinued the use of Advagraf, had been lost the follow-up or had lost the graft. The mean age of the 199 patients was 51.5 ± 10.4 years (60.8% male). The mean time from transplantation to the conversion to Advagraf was 8.3 ± 3.2 years and the mean tacrolimus trough level at conversion was 4.2 ± 1.4 ng/ml. After conversion, 147 patients (73.8 %) had a reduced trough level at one month and the mean change in trough level postconversion was -13.5%. The mean serum creatinine level between conversion and six months postconversion was not significantly different (1.12 ± 0.36 vs 1.10 ± 0.42 mg/dl). Thirty-four patients (17%) discontinued the treatment with Advagraf and two (1%) developed biopsy-proved acute rejection. In conclusion, frequent conversion caused by a high discontinuation rate may further raise the potential risk of allograft rejection and increase unnecessary cost. In view of this, the policy of converting to Advagraf with the purpose of improving medical adherence should be individualised in routine clinical practice.